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4. Abstract 
Aptamers (small oligonucleotide sequences) are being selected that specifically recognize 
methamphetamine. The aptamers will be used for the development of a highly sensitive 
fluorescence-based assay. The work has progressed such that a population seems to be evolving 
that binds methamphetamine. 
5. Project Description 
The current project was to develop aptamers that recognize methamphetamine for the purpose of 
both detection and preventing methamphetamine effects. The reason fortaking on this projectwas 
the possibility that we could provide a new reagent for combating the high level of 
methamphetamine abuse in the USA, which was described by the director of the NlDA as "an 
extremely serious and growing problem" [I]. Methamphetamine is a frequently used illicit drug in 
California and Hawaii; particularly in cities such as San Diego, San Francisco, and Honolulu. In 
San Diego. methamphetamine is currently the most frequently abused drug. Methamphetamine 
traffic has increased significantly in Arizona, Colorado, Iowa, Minnesota, Missouri, Nebraska and 
Washington. Methamphetamine abuse among teenagers is now common in the Midwest. An 
Department of Justice report states "an expert associated with Juvenile Court Services in Marshall 
County, Iowa, estimated in 1998 that one-third of the 1,600 students at Marshalltown High School 
had tried methamphetamine" 121. Between 1994 and 1999 methamphetamine arrests rose almost 
4-fold and methamphetamine lab seizures increased about 8-fold. 
Two forms of amphetamine are Crank (a general term referring to a variety of forms of 
methamphetamine) and Ice (a crystalline methamphetamine that can be smoked). 
Methamphetamine effects are long lasting and continue to cause damage long after the user has 
stopped taking the drug. Long-term effects can include fatal kidney and lung disorders, possible 
brain damage, depression, hallucinations, disorganized lifestyle, permanent psychological 
problems, violent and aggressive behavior, weight loss, insomnia, behavior resembling paranoid 
schizophrenia, decreased social life, malnutrition, poor coping abilities, disturbance of personality 
development, lowered resistance to illnesses, liver damage, stroke, and death. Although the main 
effects are on the individual user, there are several significant effects of methamphetamine use on 
society. Societal impacts include the effects on others of car crashes, crimes, fires due to 
explosions from the illegal manufacture of methamphetamines, and hazardous waste. If 
methamphetamines are used during pregnancy, the resulting babies tend to be asocial, incapable 
of bonding, cry for 24 hours without stopping, and have tremors and/or birth defects. 
Aptamers are small nucleic acids that avidly and selectively bind small ligands with affinities in the 
nanomolar to picomolar range and exquisite specificities [3]. For example, aptamers have been 
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isolated that distinguish caffeine from theophylline that differ by only a single methyl group [4] and 
that distinguish tyramine and dopamine that differ by a single hydroxyl group [5]. 
Many aptamers consist of a stem-loop structure in which the bases in the loop and the stem are 
intimately involved in the interaction with the ligand. These small nucleic acids can be selected 
by in vitro mutagenesis in a procedure called SELEX (systematic evolution of ligands by exponential 
enrichment) [E, 71. DNA aptamers have been isolated to a variety of structures that include proteins 
and small molecules. Examples of ssDNA aptamers include aptamers that recognize thrombin, HIV 
reverse transcriptase, bile acids, cocaine, L-selectin, arginine, L-tyrosinamide and IgE [8-151. The 
use of aptamers to analyze mind-altering drugs has already been demonstrated with a ssDNA 
aptamer that recognizes cocaine and that is the basis of a fluorescence quenching-based assay 
for analyzing cocaine 1121. 
Despite the suitability of aptamers to microarray formats, aptamer microarrays have not yet been 
developed and the microarray format for aptamers is itself a very new concept. For example, the 
term aptamer does not appear in the microarray glossary presented presented by the Cambridge 
Healthtech Institute as of March 2002. The companies, Curagen and Somalogic have announced 
plans to develop microarrays of aptamers for detecting proteins in biological samples. But, to our 
knowledge, no plans have been announced for developing microarrays for detecting drugs or other 
small molecules. 
6. Project Objectives: 
The long-term goal of this project is to produce an aptamer microarray that can be used as a 
screening tool for a variety of drugs to provide forensics investigators with a rapid screening 
procedure for many common drugs. The following specific aims are proposed: 1) select for DNA 
aptamer(s) that recognizes methamphetamine 2) clone and characterize the isolated aptamer(s). 
The aptamer could improve forensic science in crime laboratories by providing a new reagent for 
detecting methamphetamine in field samples where there is not direct evidence of 
methamphetamine synthesis. We anticipate that the aptamer(s) developed in this exploratory 
project will be directly applicable to the development of a homogeneous assay for 
methamphetamine that can be used to analyze samples for methamphetamine and other drugs. 
Aptamers can also be assembled as part of a microarray for analyzing series of drugs. Aptamer 
microarrays will have several advantages over immunoassays for the rapid screening of biological 
samples. Chief amongst these advantages are that: 1) The microarrays will be stable even when 
dehydrated and will be adaptable to mobile equipment, and 2) New aptamers can be rapidly 
"evolved" in the laboratory. Thus, the aptamer technology will be able to keep up with the 
introduction of new drugs and changes in drug use over time. 
The aptamer(s) might also be applied towards decreasing a person's response to 
methamphetamine. As a prototype for this type of approach, an aptamer that recognizes cocaine 
has been recently developed to be used to combat cocaine addiction [IE]. 
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7. Procedures 
A methamphetamine-linked magnetic beads were used to select for the aptamer. First, the 
compound (Fig. 1) was prepared from the methyl ester of paraformylbenzoic acid and nitroethane 
and a primary amine in 78% yield (Kraus, unpublished). The crystalline product was then reduced 
in two steps to the amino ester which is hydrolyzed to the acid with lithium hydroxide (final yield , 
49%). Methamphetamine-linked magnetic beads were used to select for the aptamer. First, the 
compound (Fig. 1) was prepared from the methyl ester of paraformylbenzoic acid and nitroethane 
and a primary amine in 78% yield (Kraus, unpublished). The crystalline product was then reduced 
in two steps to the amino ester which is hydrolyzed to the acid with lithium hydroxide (final yield , 
49%). Dr. Kraus then employed the succinimidyl ester of biotin with the amine produced from the 
reaction of the resorcinol spacer with the chlorocarbonyl derivative of methamphetamine. The 
metamphetamine-Bnitro-(l ,3 bis, amino-ethane)-resorcinol was then coupled to amine-reactive 
Dynabeads M-270 Epoxy according to the manufacturer's instructions to form the affinity resin. 
We followed a procedure for making single stranded DNA (ssDNA) aptamers that has been 
previously described [6, 13, 171. A mix of 2 nmole of randomly varied ssDNAs (1.4 x I O l 5  different 
sequences) was passed multiple times through a methamphetamine-agarose column with 
intervening PCR amplifications to introduce new variations into the sequence. 
The methamphetamine-binding ssDNAs were removed from the affinity beads at each round by 
heating the beads and PCR was performed with the beads present. After each round, the pool size 
ofthe DNA in the mixture was monitored by determining the percent of total loaded ssDNA that was 
adsorbed and eluted from the affinity column. Negative selections against the beads with 
methamphetamine were also included. 
8. Results/ Discussion 
The project consisted of two parts. The first part of the project was the chemical synthesis of 
methamphetamine derivatives that were then used for the second part of the project, which was to 
select aptamers that specifically bound to methamphetamine. 
Part one was successfully 
completed. First, the compound 
was prepared from the methyl 
ester of paraformylbenzoic acid 
and nitroethane and a primary 
amine in 78% yield (Kraus, 
unpublished). The crystalline 
product was then reduced in two 
stem to the amino ester which is 
Figure 1. Resorcinol derivative of methampetamine 
hydrolyzed to the acid with lithium hydroxide (final yield, 49%). Dr. Kraus then employed the 
succinimidyl ester of biotin with the amine produced from the reaction of the resorcinol spacer with 
the chlorocarbonyl derivative of methamphetamine. The metamphetamine-2-nitro-(l,3 bis. 
amino-ethane)-resorcinol (Fig. 1) was then coupled to amine-reactive Dynabeads M-270 Epoxy 
according to the manufacturer's instructions to form the affinity resin. 
Selection for a DNA aptamer was done according to the protocol outlined in Fig 2. Two sets of 
selections were performed. The first was taken through 13 rounds until it was determined that 
nothing was evolving from the original pool. The second selection was taken through 7 rounds and 
seems to be evolving an aptamer as shown in figure 3. The percent of the pool that bound the 
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methamphetamine on the affinity matrix increased dramatically on round 6. Because of this the 
conditions were made more stringent forthe next round (7) and the number ofwashes of the matrix 
after binding the DNA were increased from one 
to 10. Even so the percent of the pool that 
bound the methamphetamine affinity matrix 
increased compared with round 5. 
9. Dissemination Discussion 
Although the project has not reached completion, 
we have reasonably good evidence that an 
aptamer is evolving in our pool. The team is 
looking for opportunities for further funding to 
complete the project. Once an aptamer is 
selected, the results of the current proposed 
research will be disseminated by publication in 
research journals. The results of these studies Figure 2. Selection protocol for a DNA 
will then be used to develop a microarray or aptamer. The figure demonstrates a single 
other assay for methamphetamine and other round of selection using an affinity matrix 
drugs that can be used for the detection of these consisting of methamphetamine linked to 
drugs at the crime scene and in the laboratory magnetic beads by way of a resorcinol bridge. 
I O .  Discussion of problems that have arisen. 
When we started this project we were unaware of 
the amount of time that it would take to develop 
and optimize the aptamer selection. Therefore, 
we underestimated the amount of work that we 
could accomplish within the resources of the 
current grant. The better understanding of the 
true effort required for optimization of the 
protocols and aptamer selection that we have 
learned from these studies will help us to more 
appropriately define the necessary resources and 
time for completing this project. The results 
obtained from this project will contribute to the 
preliminary results used as a basis for obtaining 
further resources to complete the project. 2 3 4 5 6 7  
SELEX round 
Figure 3. Selection of a methamphetamine 
aptamer. In this selection experiments seven 
rounds of selection were performed and the 
percent of the pool that bound to the column 
was determined at each round. These results 
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